Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters

Cardiovascular Drugs and Therapy
B SilkeF Harrison

Abstract

Using an echo-Doppler method (Quantascope), the hemodynamic profile of the calcium channel antagonist elgodipine (64 micrograms/kg, i.v.) was investigated in 22 patients with angina pectoris at rest and during exercise. A placebo control was used. At rest, elgodipine significantly decreased systemic vascular resistance as well as systolic and diastolic blood pressure, while increasing cardiac output and stroke volume. During supine bicycle exercise the constant workload, elgodipine significantly increased cardiac output and stroke volume, and decrease the rate-pressure-product (double product); the exercise systolic blood pressure was decreased without change in the diastolic component. Elgodipine significantly reduced the incidence and severity (self-rated pain score) of exercise-induced anginal systems. Heart rate was not affected by elgodipine, either at rest or during exercise. In particular, no negative inotropy could be inferred from the echo-Doppler data. In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a "shallow" and a "deep" compartment. The hemodynamic data in...Continue Reading

References

Jan 1, 1979·Ultrasonic Imaging·C F Hottinger, J D Meindl
Jan 1, 1979·Medical & Biological Engineering & Computing·M Ramsey
May 1, 1992·The American Journal of Cardiology·H SuryapranataP W Serruys
Jun 1, 1992·Clinical Pharmacokinetics·J G Kelly, K O'Malley
Apr 1, 1990·British Journal of Clinical Pharmacology·B SilkeS H Taylor
Jan 1, 1985·British Journal of Clinical Pharmacology·B SilkeS H Taylor
Jan 1, 1988·British Journal of Anaesthesia·S H Taylor, B Silke
Feb 1, 1987·British Journal of Clinical Pharmacology·B SilkeS H Taylor
Dec 1, 1985·British Journal of Clinical Pharmacology·B SilkeS H Taylor
Mar 1, 1984·Anaesthesia·P HuttonC Prys-Roberts
Jan 1, 1994·British Journal of Pharmacology·C D Drieu la RochelleS E O'Connor

❮ Previous
Next ❯

Citations

May 5, 2006·Current Hypertension Reports·Josep Redon, Jose M Pascual

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.